Estimated costs of ADEs vary with methodology used

Estimated costs of ADEs vary with methodology used PharmacoEconomics & Outcomes News 784, p16 - 12 Aug 2017 Estimated costs of ADEs vary with methodology used Estimated costs of adverse drug events (ADEs) in adults in Sweden vary with the methodology used, according to findings of study published in Value in Health. ADEs identified from medical records in a random sample of 4970 Swedish adults over a 3-month period in 2008 were assessed for causality, and their costs were estimated using five evaluation methods: diagnostic code method, main diagnosis method, proportion of registered costs method, resource use method, and unit cost method. Maximum estimated direct healthcare costs due to ADEs ranged from €1538 using the diagnostic code method to €413 770 using the unit cost method. However, the cost per patient ranged from €0 to €500 using the diagnostic code method and unit cost method, respectively, under the most conservative definitions for ADE-related healthcare resource use and causality. "The estimated costs for ADEs were highly affected by the choice of the costing methods, and by applying different thresholds for the uncertainty of a causal connection between the drug and the suspected ADE (step 1 of the cost evaluation) as well as between the ADE and the use of health care resources (step 2). In particular, costing methods based on manual assessment of resource use due to ADEs resulted in higher cost estimates than did methods based on registered diagnoses," said the authors. * 2016 euros Gyllensten H, et al. Comparing Methods for Estimating Direct Costs of Adverse Drug Events. Value in Health : 25 Jul 2017. Available from: URL: https:// 803261497 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784 PharmacoEconomics & Outcomes News Springer Journals

Estimated costs of ADEs vary with methodology used

1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial